Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Reduced Acetyl-l-carnitine (ALC) levels are linked to major depressive disorder (MDD) and bipolar disorder (BD).
• ALC deficiency may impair mitochondrial function, neuroplasticity, and neurotransmission, contributing to mood disorders.
• ALC's psychopharmacological potential is gaining attention for mood disorder treatment.

Purpose of the Study:

• To review and synthesize evidence on Acetyl-l-carnitine (ALC) use in treating major depressive disorder (MDD) and bipolar disorder (BD).
• To evaluate ALC's efficacy, safety, and potential as a biomarker for mood disorders.

Main Methods:

• Systematic review and meta-analysis of 15 studies (10 included in meta-analysis).
• Included 14 randomized controlled trials (RCTs) and 1 open-label study with 809 participants.
• Analyzed clinical outcomes, efficacy compared to placebo and standard antidepressants, and adverse effects.

Main Results:

• Acetyl-l-carnitine (ALC) significantly reduced depressive symptoms compared to placebo.
• ALC demonstrated comparable efficacy to standard antidepressants with a better safety profile.
• Subgroup analyses indicated greater benefits in older adults and individuals with treatment-resistant depression.

Conclusions:

• Acetyl-l-carnitine (ALC) shows promise as a therapeutic agent and potential biomarker for mood disorders like MDD and BD.
• ALC offers a potentially effective treatment option with fewer adverse effects than some standard antidepressants.
• Further large-scale longitudinal research is necessary to fully establish ALC's clinical utility and understand its mechanisms in mood disorders.